The clinical-stage company’s lead target is dotinurad, which is a once-daily oral URAT1 inhibitor designed to treat gout – a painful inflammatory condition affecting millions globally. The funds will fuel Crystalys’ clinical development program. This includes two ongoing Phase III registration-directed trials named RUBY and Topaz (NCT07089875) and a Phase II study named AMETHYST (NCT07535034). The trials are designed to evaluate dotinurad across a spectrum of gout patients, including those with limited treatment options who represent a significant unmet medical need. Related:Sobi’s $950m acquisition of Arthrosi to expand gout pipelineStrong investor confidenceThe Series B round attracted a roster of both new and returning investors.